
IQVIA Hlds (IQV) Stock Forecast & Price Target
IQVIA Hlds (IQV) Analyst Ratings
Bulls say
IQVIA Holdings is experiencing robust growth across its segments, particularly in its FSP, RWE, and CSMS divisions, which demonstrated year-over-year improvements in Q3. The company has also observed a positive shift in the commercial side, marked by enhanced client decision timelines and a strong pipeline fueled by recent drug launches, as indicated by a low-teens year-over-year growth in RFP flow. Furthermore, IQVIA's win rate has markedly increased, and the pricing environment has improved, allowing the company to strategically walk away from less favorable deals, thereby positioning itself for a projected growth rate of over 4% in its R&D Services segment on a constant currency, ex-COVID basis.
Bears say
IQVIA Holdings has experienced a decline in year-over-year constant currency growth, with a significant drop from 6.8% in the second quarter of 2025 to 3.8% in the most recent report, highlighting challenges in maintaining growth momentum. The company's guidance indicates that it would be disappointed if 2026 revenue growth falls below 5%, which raises concerns about its ability to meet investor expectations amid worsening revenue growth trends. Additionally, operational challenges, such as low hiring rates and the impact of passthrough costs on margins, coupled with external pressures like rising interest rates, further contribute to a negative outlook for the company's financial performance.
This aggregate rating is based on analysts' research of IQVIA Hlds and is not a guaranteed prediction by Public.com or investment advice.
IQVIA Hlds (IQV) Analyst Forecast & Price Prediction
Start investing in IQVIA Hlds (IQV)
Order type
Buy in
Order amount
Est. shares
0 shares